An Integrated Model to Increase Medication Recognition and Reconciliation in Oncologic Patients
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 100
- Locations
- 2
- Primary Endpoint
- medication recognition and reconciliation maintenance
Study Overview
Brief Summary
To improve medication reconciliation in oncologic patients in healthcare transitions through an alliance between a Cancer Institute and the community pharmacies and a new integrated IT platform.
Detailed Description
This trial will explore the alliance between a Cancer Institute and the community pharmacies to improve medication reconciliation in healthcare transitions, and will validate a new integrated IT platform.
Cancer patients receiving an oncologic treatment will be asked to choose a pharmacy participating to the trial, and to perform the pharmacological survey before every cycle of chemotherapy.
This will be sent through the new IT platform to the electronic medical record of IRST, and the Oncologist will perform the reconciliation.
Data about concomitant medications and possible interactions will be exensively analyzed.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Health Services Research
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Adult ≥18 years old
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤1
- •Patients receiving an anticancer treatment
- •Clear understanding of the Italian language; written informed consent.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
medication recognition and reconciliation maintenance
Time Frame: At day 1 of each cycle of treatment (each cycle might be 14, 21 or 28 days)
number of reconciliations per patient
Secondary Outcomes
No secondary outcomes reported